- Shares of Athersys (NASDAQ:ATHX +6.6%) are trading notably higher on heavy volume.
- Perhaps helping to tip sentiment is SA contributor U.S. Biotech Investor, who highlights results from preclinical studies of MultiStem and says "investors are beginning to recognize and appreciate the potential value of the [company's] portfolio."
- The author (who penned a bullish post on the shares back in November) says reforms in Japanese pharmaceutical legislation and new information gleaned from Piper Jaffray's healthcare conference have created even more upside for the stock, which, according to the article, could go to $15.